医学
前列腺癌
医学物理学
医学影像学
癌症影像学
放射科
癌症
内科学
作者
Raquel Pérez-López,Nina Tunariu,Anwar R. Padhani,Wim J.G. Oyen,Stefano Fanti,Hebert Alberto Vargas,Aurelius Omlin,Michael J. Morris,Johann S. de Bono,Dow‐Mu Koh
出处
期刊:Radiology
[Radiological Society of North America]
日期:2019-06-25
卷期号:292 (2): 273-286
被引量:57
标识
DOI:10.1148/radiol.2019181931
摘要
The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, more precise imaging may help physicians deliver better care. More accurate local staging and earlier detection of metastatic disease, accurate identification of oligometastatic disease, and optimal assessment of treatment response are areas where modern imaging is rapidly evolving and expanding. Next-generation imaging modalities, including whole-body MRI and molecular imaging with combined PET and CT and combined PET and MRI using novel radiopharmaceuticals, create new opportunities for imaging to support and refine management pathways in patients with advanced prostate cancer. This article demonstrates the potential and challenges of applying next-generation imaging to deliver the clinical promise of treatment breakthroughs. © RSNA, 2019 Online supplemental material is available for this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI